Target intelligence / Profile preview

Transgelin-3 (TAGLN3)

Target
TAGLN3
Molecular classification
Other (actin-binding protein), Cytoskeletal protein, Member of the calponin family
01

Overview

Transgelin-3 (TAGLN3) is a cytoskeletal protein within the calponin family, distinguished by a calponin homology (CH) domain, a single actin-binding site, and a C-terminal CLIK motif[3]. It consists of 199 amino acids and is highly conserved across vertebrates, with the human TAGLN3 gene located on chromosome 3q13.2[3]. Transgelin-3 is predominantly expressed in neural cells and plays roles in actin filament regulation, impacting neurite outgrowth, cell migration, neuronal differentiation, and possibly synapse formation[2][3]. It was originally discovered in the rat brain as NP25 and is mainly associated with the growth and differentiation of neuronal circuits. Although related transgelin/calponin family proteins have been implicated in cancer and inflammatory processes, there is currently no evidence that TAGLN3 itself serves as a therapeutic drug target or established biomarker. Its principal biological role appears to be in cytoskeletal organization, especially in neural tissues[2][3].

Other names
NP25NP22Neuronal protein 22Neuronal protein NP25NP24hNP22tgln3
02

Biological functions

Regulation of actin cytoskeleton structure and dynamicsCell migrationNeurite outgrowth and neuronal differentiationCell motility
03

Disease associations

Neurodevelopmental and neuropsychiatric disorders (suggested by altered expression in alcoholic brain)Cancer (inferred from role of calponin/transgelin family in tumorigenesis)Other (exact role in disease is still unclear)

Beyond the preview

Go deeper on Transgelin-3 (TAGLN3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transgelin-3 (TAGLN3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call